Start-up
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreEnrolling
Integrating cognitive-behavioural therapy for social anxiety disorder with HIV risk reduction counselling for HIV-negative gay and bisexual men who are at high risk for HIV
Learn MoreCompleted
Transgender women removing healthcare barriers to engagement in the HIV prevention and care cascades
Learn MoreStart-up
Preventing HIV by targeting the immune system instead of the virus
Learn MoreEnrolling
Enrolling
Improving vaginal health to decrease biological risk of HIV-1 infection in Canadian ACB women
Learn MoreEnrolling
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy — A Pilot Feasibility Study
Learn MoreStart-up
Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
